Promise and challenge of RNA interference-based therapy for cancer

Journal of Clinical Oncology

Volumn 29, Issue 6, 2011, Pages 747-754

  Petrocca, Fabio ^a   Lieberman, Judy ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LET 7; LIPOSOME; LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 106; MICRORNA 141; MICRORNA 15; MICRORNA 155; MICRORNA 16; MICRORNA 17; MICRORNA 19; MICRORNA 20; MICRORNA 200; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 24; MICRORNA 25; MICRORNA 26; MICRORNA 335; MICRORNA 34; MICRORNA 372; MICRORNA 373; MICRORNA 92; MICRORNA 93; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE 2; SMALL INTERFERING RNA; STABLE NUCLEIC ACID LIPID PARTICLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

B CELL LEUKEMIA; B CELL LYMPHOMA; BILE DUCT CANCER; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DRUG DOSE ESCALATION; EPIGENETICS; EWING SARCOMA; GENE EXPRESSION; GENE SILENCING; GERM CELL TUMOR; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; STOMACH CANCER; THYROID CANCER;

CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 79952180081     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.6287     Document Type: Review

References (80)

1. Fire A, Xu S, Montgomery MK, et al: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811, 1998 (Pubitemid 28099681)
2. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843-854, 1993 (Pubitemid 24014542)
3. Ghildiyal M, Zamore PD: Small silencing RNAs: An expanding universe. Nat Rev Genet 10: 94-108, 2009
4. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297, 2004
5. Ambros V: The functions of animal microRNAs. Nature 431:350-355, 2004
6. Friedman RC, Farh KK, Burge CB, et al: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19:92-105, 2009
7. Krek A, Grün D, Poy MN, et al: Combinatorial microRNA target predictions. Nat Genet 37:495-500, 2005 (Pubitemid 40617277)
8. Shell S, Park SM, Radjabi AR, et al: Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 104:11400-11405, 2007 (Pubitemid 47175152)
9. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435:834-838, 2005 (Pubitemid 40839735)
10. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103:2257-2261, 2006 (Pubitemid 43271657)
11. Rosenfeld N, Aharonov R, Meiri E, et al: MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26:462-469, 2008 (Pubitemid 351501813)
12. Iorio MV, Visone R, Di Leva G, et al: MicroRNA signatures in human ovarian cancer. Cancer Res 67:8699-8707, 2007 (Pubitemid 47437445)
13. Calin GA, Ferracin M, Cimmino A, et al: A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793-1801, 2005 (Pubitemid 41549891)
14. Ventura A, Jacks T: MicroRNAs and cancer: Short RNAs go a long way. Cell 136:586-591, 2009
15. Dews M, Homayouni A, Yu D, et al: Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38:1060-1065, 2006 (Pubitemid 44325933)
16. Nicoloso MS, Spizzo R, Shimizu M, et al: MicroRNAs: The micro steering wheel of tumour metastases. Nat Rev Cancer 9:293-302, 2009
17. Valastyan S, Reinhardt F, Benaich N, et al: A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137:1032-1046, 2009
18. Tavazoie SF, Alarcón C, Oskarsson T, et al: Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451:147-152, 2008
19. Ma L, Weinberg RA: MicroRNAs in malignant progression. Cell Cycle 7:570-572, 2008 (Pubitemid 351498993)
20. Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99:15524-15529, 2002 (Pubitemid 35403967)
21. Klein U, Lia M, Crespo M, et al: The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17:28-40, 2010
22. Raveche ES, Salerno E, Scaglione BJ, et al: Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 109:5079-5086, 2007 (Pubitemid 46890521)
23. Cimmino A, Calin GA, Fabbri M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 102:13944-13949, 2005 (Pubitemid 41377683)
24. Calin GA, Sevignani C, Dumitru CD, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101:2999-3004, 2004 (Pubitemid 38327724)
25. Newman MA, Thomson JM, Hammond SM: Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 14: 1539-1549, 2008
26. Viswanathan SR, Daley GQ, Gregory RI: Selective blockade of microRNA processing by Lin28. Science 320:97-100, 2008 (Pubitemid 351490762)
27. Hagan JP, Piskounova E, Gregory RI: Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nat Struct Mol Biol 16:1021-1025, 2009
28. Heo I, Joo C, Kim YK, et al: TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell 138:696-708, 2009
29. Lehrbach NJ, Armisen J, Lightfoot HL, et al: LIN-28 and the poly(U) polymerase PUP-2 regulate let-7 microRNA processing in Caenorhabditis elegans. Nat Struct Mol Biol 16:1016-1020, 2009
30. Petrocca F, Visone R, Onelli MR, et al: E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13:272-286, 2008 (Pubitemid 351318375)
31. Chang TC, Wentzel EA, Kent OA, et al: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26:745-752, 2007 (Pubitemid 46856245)
32. O'Donnell KA, Wentzel EA, Zeller KI, et al: c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435:839-843, 2005 (Pubitemid 40839736)
33. Lal A, Navarro F, Maher CA, et al: miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3′UTR microRNA recognition elements. Mol Cell 35:610-625, 2009
34. Woods K, Thomson JM, Hammond SM: Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem 282:2130-2134, 2007 (Pubitemid 47076737)
35. Saito Y, Liang G, Egger G, et al: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9:435-443, 2006 (Pubitemid 43832188)
36. Köbel M, Gilks CB, Huntsman DG: Dicer and Drosha in ovarian cancer. N Engl J Med 360:1150-1151; author reply 1151, 2009
37. West JA, Viswanathan SR, Yabuuchi A, et al: A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature 460:909-913, 2009
38. Mayr C, Bartel DP: Widespread shortening of 3′UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138:673-684, 2009
39. Mayr C, Hemann MT, Bartel DP: Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315:1576-1579, 2007 (Pubitemid 46449474)
40. Elbashir SM, Harborth J, Lendeckel W, et al: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001 (Pubitemid 32494397)
41. Meister G, Tuschl T: Mechanisms of gene silencing by double-stranded RNA. Nature 431:343-349, 2004 (Pubitemid 39265674)
42. Jackson AL, Bartz SR, Schelter J, et al: Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21:635-637, 2003 (Pubitemid 36638089)
43. Sioud M: Does the understanding of immune activation by RNA predict the design of safe siRNAs? Front Biosci 13:4379-4392, 2008
44. Sioud M: Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol Med 12: 167-176, 2006
45. Sledz CA, Holko M, de Veer MJ, et al: Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5:834-839, 2003 (Pubitemid 37087172)
46. Kleinman ME, Yamada K, Takeda A, et al: Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591-597, 2008 (Pubitemid 351483358)
47. Hornung V, Guenthner-Biller M, Bourquin C, et al: Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11:263-270, 2005 (Pubitemid 40460553)
48. Poeck H, Besch R, Maihoefer C, et al: 5′-Triphosphate-siRNA: Turning gene silencing and Rig-I activation against melanoma. Nat Med 14: 1256-1263, 2008
49. Yu F, Yao H, Zhu P, et al: Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131:1109-1123, 2007 (Pubitemid 350235025)
50. Sun F, Fu H, Liu Q, et al: Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 582:1564-1568, 2008
51. Yamakuchi M, Ferlito M, Lowenstein CJ: miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 105:13421-13426, 2008
52. Navarro F, Gutman D, Meire E, et al: miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53. Blood 114:2181-2192, 2009
53. Kota J, Chivukula RR, O'Donnell KA, et al: Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017, 2009
54. He L, He X, Lim LP, et al: A microRNA component of the p53 tumour suppressor network. Nature 447:1130-1134, 2007 (Pubitemid 47014436)
55. Raver-Shapira N, Marciano E, Meiri E, et al: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26:731-743, 2007 (Pubitemid 46856247)
56. Lal A, Pan Y, Navarro F, et al: miR-24- mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat Struct Mol Biol 16:492-498, 2009
57. Weidhaas JB, Babar I, Nallur SM, et al: MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 67:11111-11116, 2007 (Pubitemid 350248533)
58. Zenz T, Mohr J, Eldering E, et al: miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113:3801-3808, 2009
59. Kumar MS, Erkeland SJ, Pester RE, et al: Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A 105:3903-3908, 2008 (Pubitemid 351723497)
60. Esquela-Kerscher A, Trang P, Wiggins JF, et al: The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7:759-764, 2008 (Pubitemid 351520040)
61. Xiao C, Srinivasan L, Calado DP, et al: Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9:405-414, 2008 (Pubitemid 351405110)
62. Koralov SB, Muljo SA, Galler GR, et al: Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 132:860-874, 2008 (Pubitemid 351312808)
63. Costinean S, Zanesi N, Pekarsky Y, et al: Pre-B cell proliferation and lymphoblastic leukemia/highgrade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 103:7024-7029, 2006
64. Veedu RN, Wengel J: Locked nucleic acid as a novel class of therapeutic agents. RNA Biol 6:321-323, 2009
65. Elmén J, Lindow M, Schütz S, et al: LNA-mediated microRNA silencing in non-human primates. Nature 452:896-899, 2008 (Pubitemid 351550859)
66. Scholl C, Fröhling S, Dunn IF, et al: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137:821-834, 2009
67. Kedmi R, Peer D: RNAi nanoparticles in the service of personalized medicine. Nanomedicine (Lond) 4:853-855, 2009
68. de Fougerolles A, Vornlocher HP, Maraganore J, et al: Interfering with disease: A progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6:443-453, 2007 (Pubitemid 47064567)
69. Whitehead KA, Langer R, Anderson DG: Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov 8:129-138, 2009
70. de Fougerolles AR: Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 19:125-132, 2008
71. Krützfeldt J, Rajewsky N, Braich R, et al: Silencing of microRNAs in vivo with 'antagomirs'. Nature 438:685-689, 2005
72. Zimmermann TS, Lee AC, Akinc A, et al: RNAi-mediated gene silencing in non-human primates. Nature 441:111-114, 2006
73. Wu Y, Navarro F, Lal A, et al: Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe 5:84-94, 2009
74. Palliser D, Chowdhury D, Wang QY, et al: An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439:89-94, 2006 (Pubitemid 43053634)
75. Wolfrum C, Shi S, Jayaprakash KN, et al: Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25:1149-1157, 2007 (Pubitemid 47538115)
76. Davis ME: The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol Pharm 6:659-668, 2009
77. Bartlett DW, Davis ME: Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng 99:975-985, 2008 (Pubitemid 351316639)
78. Davis ME, Zuckerman JE, Choi CH, et al: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067-1070, 2010
79. Greenberger LM, Horak ID, Filpula D, et al: A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 7:3598-3608, 2008
80. Morrissey DV, Lockridge JA, Shaw L, et al: Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007, 2005 (Pubitemid 41114035)